Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, May 22, 2015, 89 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,297.00 to $237,892,500.00.

Highlighted Stocks Traded by Insiders:

Paycom Software (PAYC) - FREE Research Report

WCAS Capital Partners IV, L.P., who is 10% Owner at Paycom Software, sold 54,154 shares at $35.75 on May 22, 2015. Following this transaction, the 10% Owner owned 126,271 shares meaning that the stake was reduced by 30.01% with the 54,154-share transaction.

Welsh, Carson, Anderson & Stowe X, L.P., who is 10% Owner at Paycom Software, sold 5.1 million shares at $35.75 on May 22, 2015. Following this transaction, the 10% Owner owned 11.9 million shares meaning that the stake was reduced by 30.02% with the 5.1 million-share transaction.

The shares most recently traded at $34.64, down $1.11, or 3.2% since the insider transaction. Historical insider transactions for Paycom Software go as follows:

  • 4-Week # shares bought: 4,000
  • 4-Week # shares sold: 5.6 million
  • 12-Week # shares bought: 4,000
  • 12-Week # shares sold: 5.6 million
  • 24-Week # shares bought: 4,500
  • 24-Week # shares sold: 17.2 million

The average volume for Paycom Software has been 493,100 shares per day over the past 30 days. Paycom Software has a market cap of $2.1 billion and is part of the technology sector and computer software & services industry. Shares are up 35.47% year-to-date as of the close of trading on Friday.

Paycom Software, Inc. offers cloud-based human capital management (HCM) software solutions delivered as Software-as-a-Service in the United States. It provides functionality and data analytics that businesses need to manage the complete employment life cycle from recruitment to retirement. The company has a P/E ratio of 178.3. Currently, there are 5 analysts who rate Paycom Software a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on PAYC - FREE

TheStreet Quant Ratings

rates Paycom Software as a

hold

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, robust revenue growth and notable return on equity. However, as a counter to these strengths, we also find weaknesses including premium valuation and generally higher debt management risk. Get the full

Paycom Software Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Edwards Lifesciences (EW) - FREE Research Report

Mcneil Barbara J, who is Director at Edwards Lifesciences, sold 2,000 shares at $132.59 on May 22, 2015. Following this transaction, the Director owned 52,563 shares meaning that the stake was reduced by 3.67% with the 2,000-share transaction.

The shares most recently traded at $128.62, down $3.97, or 3.09% since the insider transaction. Historical insider transactions for Edwards Lifesciences go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 2,000
  • 24-Week # shares sold: 2,000

The average volume for Edwards Lifesciences has been 1.1 million shares per day over the past 30 days. Edwards Lifesciences has a market cap of $14.1 billion and is part of the health care sector and health services industry. Shares are up 2.75% year-to-date as of the close of trading on Friday.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company has a P/E ratio of 16.3. Currently, there are 9 analysts who rate Edwards Lifesciences a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EW - FREE

TheStreet Quant Ratings

rates Edwards Lifesciences as a

buy

. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Edwards Lifesciences Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

South State (SSB) - FREE Research Report

Battiste Luther J Iii, who is Director at South State, sold 2,500 shares at $72.23 on May 22, 2015. Following this transaction, the Director owned 5,998 shares meaning that the stake was reduced by 29.42% with the 2,500-share transaction.

The shares most recently traded at $70.39, down $1.84, or 2.61% since the insider transaction. Historical insider transactions for South State go as follows:

  • 4-Week # shares bought: 310
  • 4-Week # shares sold: 6,500
  • 12-Week # shares bought: 310
  • 12-Week # shares sold: 6,500
  • 24-Week # shares bought: 1,310
  • 24-Week # shares sold: 6,850

The average volume for South State has been 83,800 shares per day over the past 30 days. South State has a market cap of $1.7 billion and is part of the financial sector and banking industry. Shares are up 6.44% year-to-date as of the close of trading on Friday.

South State Corporation operates as the bank holding company for South State Bank that provides a range of retail and commercial banking services, mortgage lending services, trust and investment services, and consumer finance loans. The stock currently has a dividend yield of 1.34%. The company has a P/E ratio of 20.9. Currently, there are 4 analysts who rate South State a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SSB - FREE

TheStreet Quant Ratings

rates South State as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full

South State Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.